NIBSC - Establishment of the first WHO International Standard for anti-Rift Valley fever virus antibodies

The NIBSC, in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) and partners Integrum Scientific (USA) in partnership with the Uganda Virus Research Institute (UVRI) and Technical University of Mombasa (Kenya), is currently developing the first WHO International Standard for anti-Rift Valley fever virus antibodies. (https://cepi.net/news_cepi/efforts-to-advancerift-valley-fever-vaccines-progress-with-new-cepi-partnership/)

The antibody standard is a pool of serum or plasma from multiple patients who have recovered from Rift valley fever. The intended use is to calibrate available kits and assays for the detection of antibodies specific for Rift valley fever virus; this allows comparability between the results from different laboratories, epidemiology studies, vaccine clinical trials.

We are recruiting laboratories to assess and to support the establishment of this antibody standard.

To join our collaborative study, please email our Project Lead, Giada.mattiuzzo@nibsc.org